

# **Pain Management Drugs Market By Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Anti-migraine Agents, Antidepressants, Opioids, Nonnarcotic Analgesics) , By Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, Fibromyalgia, Muscle Sprain/Strain, Bone Fracture, Acute Appendicitis, Others) By Pain Type (Chronic Pain, Acute Pain) : Global Opportunity Analysis and Industry Forecast, 2024-2033**

<https://marketpublishers.com/r/P06E1D1C434FEN.html>

Date: July 2024

Pages: 216

Price: US\$ 2,655.00 (Single User License)

ID: P06E1D1C434FEN

## **Abstracts**

### **Pain Management Drugs Market**

The pain management drugs market was valued at \$72.6 billion in 2023 and is projected to reach \$109.6 billion by 2033, growing at a CAGR of 4.2% from 2024 to 2033.

A pain management drug is medication prescribed for the alleviation of pain ranging from moderate discomfort to severe distress. The formulation of pain management drugs comprises of different drug class, including opioids, antidepressants or acetaminophen. These medications target diverse pain types, including musculoskeletal, neuropathic, and inflammatory pain. The mechanisms pertaining to the functioning of pain management drug are diverse such as lowering of inflammation, inhibition of pain signals in the nervous system, or alteration of brain chemistry to modulate the perception of pain.

Increase in the prevalence of lifestyle and chronic diseases such as stroke, heart disease, type II diabetes, and cancer is driving the pain management drugs market. In addition, advancements in drug formulations and delivery methods such as extended-release formulations with reduced dosing frequency are boosting the demand for the drugs as they enhance patient compliance & treatment outcomes. In recent times, explorations in nanotherapeutics are trending in the market as nanoparticles are anticipated to possess the capability of precisely identifying the target and offering long-term efficacy in significantly low dosage.

However, the severe side-effects of pain management drugs; including cardiovascular events, gastrointestinal bleeding, sedation, renal impairment, and respiratory depression; limit their consumption, hence presenting challenges for market expansion. To eliminate the hazards of conventional drugs, natural alternatives are being explored as they have potentially minimal side-effects. For instance, Kratom, a herbal substance obtained from the *Mitragyna speciosa* tree, is being utilized as an alternative to opioid drugs. Kratom medications have proved to be highly effective in providing relief from chronic pain conditions such as fibromyalgia & arthritis and neuropathic pain.

## Segment Review

The pain management drugs market is segmented into drug class, indication, pain type, and region. On the basis of drug class, the market is divided into NSAIDs, anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. As per indication, it is classified into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, muscle sprain/strain, bone fracture, acute appendicitis, and others. By pain type, it is bifurcated into chronic pain and acute pain. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

## Key Findings

On the basis of drug class, the opioids segment is expected to dominate the market during the forecast period.

As per indication, the postoperative pain segment is predicted to be the highest shareholder by 2033.

By pain type, the chronic pain segment is anticipated to lead the market during the forecast period.

Region wise, North America is projected to be the highest revenue generator by 2033.

### Competition Analysis

The major players operating in the global pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Endo Health Solutions, Inc., Purdue Pharma L.P., Pfizer, Inc., Viartis Inc., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

Quarterly Update and\* (only available with a corporate license, on listed price)

5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

Free Upcoming Version on the Purchase of Five and Enterprise User License.

16 analyst hours of support\* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

15% Free Customization\* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

Free data Pack on the Five and Enterprise User License. (Excel version of the report)

Free Updated report if the report is 6-12 months old or older.

24-hour priority response\*

Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines

Additional company profiles with specific client's interest

Additional country or region analysis- market size and forecast

Expanded list for Company Profiles

Historic market data

Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Class

NSAIDs

Anesthetics

Anticonvulsants

Anti-migraine Agents

Antidepressants

Opioids

Nonnarcotic Analgesics

## By Indication

Arthritic Pain

Neuropathic Pain

Cancer Pain

Chronic Back Pain

Postoperative Pain

Migraine

Fibromyalgia

Muscle Sprain/Strain

Bone Fracture

Acute Appendicitis

Others

## By Pain Type

Chronic Pain

Acute Pain

## By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia-Pacific

Japan

China

India

Australia

South Korea

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

Key Market Players

Novartis AG

Eli Lilly & Company

Abbott Laboratories

Endo Health Solutions, Inc.

Purdue Pharma L.P.

Pfizer, Inc.

Viartis Inc.

Merck & Co. Inc.

Johnson & Johnson

GlaxoSmithKline Plc

## Contents

### **CHAPTER 1: INTRODUCTION**

- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
  - 1.4.1. Primary Research
  - 1.4.2. Secondary Research
  - 1.4.3. Analyst Tools and Models

### **CHAPTER 2: EXECUTIVE SUMMARY**

- 2.1. CXO Perspective

### **CHAPTER 3: MARKET LANDSCAPE**

- 3.1. Market Definition and Scope
- 3.2. Key Findings
  - 3.2.1. Top Investment Pockets
  - 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
  - 3.3.1. Bargaining Power of Suppliers
  - 3.3.2. Threat of New Entrants
  - 3.3.3. Threat of Substitutes
  - 3.3.4. Competitive Rivalry
  - 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
  - 3.4.1. Drivers
  - 3.4.2. Restraints
  - 3.4.3. Opportunities

### **CHAPTER 4: HUMAN INSULIN MARKET, BY PRODUCT TYPE**

- 4.1. Market Overview
  - 4.1.1 Market Size and Forecast, By Product Type
- 4.2. Pains
  - 4.2.1. Key Market Trends, Growth Factors and Opportunities



- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Syringes
  - 4.3.1. Key Market Trends, Growth Factors and Opportunities
  - 4.3.2. Market Size and Forecast, By Region
  - 4.3.3. Market Share Analysis, By Country
- 4.4. Others
  - 4.4.1. Key Market Trends, Growth Factors and Opportunities
  - 4.4.2. Market Size and Forecast, By Region
  - 4.4.3. Market Share Analysis, By Country

## **CHAPTER 5: HUMAN INSULIN MARKET, BY INDICATION**

- 5.1. Market Overview
  - 5.1.1 Market Size and Forecast, By Indication
- 5.2. Type 1 Diabetes
  - 5.2.1. Key Market Trends, Growth Factors and Opportunities
  - 5.2.2. Market Size and Forecast, By Region
  - 5.2.3. Market Share Analysis, By Country
- 5.3. Type 2 Diabetes
  - 5.3.1. Key Market Trends, Growth Factors and Opportunities
  - 5.3.2. Market Size and Forecast, By Region
  - 5.3.3. Market Share Analysis, By Country
- 5.4. Gestational Diabetes
  - 5.4.1. Key Market Trends, Growth Factors and Opportunities
  - 5.4.2. Market Size and Forecast, By Region
  - 5.4.3. Market Share Analysis, By Country

## **CHAPTER 6: HUMAN INSULIN MARKET, BY TYPE OF INSULIN**

- 6.1. Market Overview
  - 6.1.1 Market Size and Forecast, By Type of Insulin
- 6.2. Rapid-acting Insulin
  - 6.2.1. Key Market Trends, Growth Factors and Opportunities
  - 6.2.2. Market Size and Forecast, By Region
  - 6.2.3. Market Share Analysis, By Country
- 6.3. Short-acting Insulin
  - 6.3.1. Key Market Trends, Growth Factors and Opportunities
  - 6.3.2. Market Size and Forecast, By Region

- 6.3.3. Market Share Analysis, By Country
- 6.4. Intermediate-acting Insulin
  - 6.4.1. Key Market Trends, Growth Factors and Opportunities
  - 6.4.2. Market Size and Forecast, By Region
  - 6.4.3. Market Share Analysis, By Country
- 6.5. Others
  - 6.5.1. Key Market Trends, Growth Factors and Opportunities
  - 6.5.2. Market Size and Forecast, By Region
  - 6.5.3. Market Share Analysis, By Country

## **CHAPTER 7: HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL**

- 7.1. Market Overview
  - 7.1.1 Market Size and Forecast, By Distribution Channel
- 7.2. Hospital Pharmacies
  - 7.2.1. Key Market Trends, Growth Factors and Opportunities
  - 7.2.2. Market Size and Forecast, By Region
  - 7.2.3. Market Share Analysis, By Country
- 7.3. Drug Stores And Retail Pharmacies
  - 7.3.1. Key Market Trends, Growth Factors and Opportunities
  - 7.3.2. Market Size and Forecast, By Region
  - 7.3.3. Market Share Analysis, By Country
- 7.4. Online Providers
  - 7.4.1. Key Market Trends, Growth Factors and Opportunities
  - 7.4.2. Market Size and Forecast, By Region
  - 7.4.3. Market Share Analysis, By Country

## **CHAPTER 8: HUMAN INSULIN MARKET, BY REGION**

- 8.1. Market Overview
  - 8.1.1 Market Size and Forecast, By Region
- 8.2. North America
  - 8.2.1. Key Market Trends and Opportunities
  - 8.2.2. Market Size and Forecast, By Product Type
  - 8.2.3. Market Size and Forecast, By Indication
  - 8.2.4. Market Size and Forecast, By Type of Insulin
  - 8.2.5. Market Size and Forecast, By Distribution Channel
  - 8.2.6. Market Size and Forecast, By Country
  - 8.2.7. U.S. Human Insulin Market

- 8.2.7.1. Market Size and Forecast, By Product Type
- 8.2.7.2. Market Size and Forecast, By Indication
- 8.2.7.3. Market Size and Forecast, By Type of Insulin
- 8.2.7.4. Market Size and Forecast, By Distribution Channel
- 8.2.8. Canada Human Insulin Market
  - 8.2.8.1. Market Size and Forecast, By Product Type
  - 8.2.8.2. Market Size and Forecast, By Indication
  - 8.2.8.3. Market Size and Forecast, By Type of Insulin
  - 8.2.8.4. Market Size and Forecast, By Distribution Channel
- 8.2.9. Mexico Human Insulin Market
  - 8.2.9.1. Market Size and Forecast, By Product Type
  - 8.2.9.2. Market Size and Forecast, By Indication
  - 8.2.9.3. Market Size and Forecast, By Type of Insulin
  - 8.2.9.4. Market Size and Forecast, By Distribution Channel
- 8.3. Europe
  - 8.3.1. Key Market Trends and Opportunities
  - 8.3.2. Market Size and Forecast, By Product Type
  - 8.3.3. Market Size and Forecast, By Indication
  - 8.3.4. Market Size and Forecast, By Type of Insulin
  - 8.3.5. Market Size and Forecast, By Distribution Channel
  - 8.3.6. Market Size and Forecast, By Country
  - 8.3.7. Germany Human Insulin Market
    - 8.3.7.1. Market Size and Forecast, By Product Type
    - 8.3.7.2. Market Size and Forecast, By Indication
    - 8.3.7.3. Market Size and Forecast, By Type of Insulin
    - 8.3.7.4. Market Size and Forecast, By Distribution Channel
  - 8.3.8. France Human Insulin Market
    - 8.3.8.1. Market Size and Forecast, By Product Type
    - 8.3.8.2. Market Size and Forecast, By Indication
    - 8.3.8.3. Market Size and Forecast, By Type of Insulin
    - 8.3.8.4. Market Size and Forecast, By Distribution Channel
  - 8.3.9. UK Human Insulin Market
    - 8.3.9.1. Market Size and Forecast, By Product Type
    - 8.3.9.2. Market Size and Forecast, By Indication
    - 8.3.9.3. Market Size and Forecast, By Type of Insulin
    - 8.3.9.4. Market Size and Forecast, By Distribution Channel
  - 8.3.10. Italy Human Insulin Market
    - 8.3.10.1. Market Size and Forecast, By Product Type
    - 8.3.10.2. Market Size and Forecast, By Indication

- 8.3.10.3. Market Size and Forecast, By Type of Insulin
- 8.3.10.4. Market Size and Forecast, By Distribution Channel
- 8.3.11. Spain Human Insulin Market
  - 8.3.11.1. Market Size and Forecast, By Product Type
  - 8.3.11.2. Market Size and Forecast, By Indication
  - 8.3.11.3. Market Size and Forecast, By Type of Insulin
  - 8.3.11.4. Market Size and Forecast, By Distribution Channel
- 8.3.12. Rest of Europe Human Insulin Market
  - 8.3.12.1. Market Size and Forecast, By Product Type
  - 8.3.12.2. Market Size and Forecast, By Indication
  - 8.3.12.3. Market Size and Forecast, By Type of Insulin
  - 8.3.12.4. Market Size and Forecast, By Distribution Channel
- 8.4. Asia-Pacific
  - 8.4.1. Key Market Trends and Opportunities
  - 8.4.2. Market Size and Forecast, By Product Type
  - 8.4.3. Market Size and Forecast, By Indication
  - 8.4.4. Market Size and Forecast, By Type of Insulin
  - 8.4.5. Market Size and Forecast, By Distribution Channel
  - 8.4.6. Market Size and Forecast, By Country
  - 8.4.7. Japan Human Insulin Market
    - 8.4.7.1. Market Size and Forecast, By Product Type
    - 8.4.7.2. Market Size and Forecast, By Indication
    - 8.4.7.3. Market Size and Forecast, By Type of Insulin
    - 8.4.7.4. Market Size and Forecast, By Distribution Channel
  - 8.4.8. China Human Insulin Market
    - 8.4.8.1. Market Size and Forecast, By Product Type
    - 8.4.8.2. Market Size and Forecast, By Indication
    - 8.4.8.3. Market Size and Forecast, By Type of Insulin
    - 8.4.8.4. Market Size and Forecast, By Distribution Channel
  - 8.4.9. India Human Insulin Market
    - 8.4.9.1. Market Size and Forecast, By Product Type
    - 8.4.9.2. Market Size and Forecast, By Indication
    - 8.4.9.3. Market Size and Forecast, By Type of Insulin
    - 8.4.9.4. Market Size and Forecast, By Distribution Channel
  - 8.4.10. Australia Human Insulin Market
    - 8.4.10.1. Market Size and Forecast, By Product Type
    - 8.4.10.2. Market Size and Forecast, By Indication
    - 8.4.10.3. Market Size and Forecast, By Type of Insulin
    - 8.4.10.4. Market Size and Forecast, By Distribution Channel

- 8.4.11. South Korea Human Insulin Market
  - 8.4.11.1. Market Size and Forecast, By Product Type
  - 8.4.11.2. Market Size and Forecast, By Indication
  - 8.4.11.3. Market Size and Forecast, By Type of Insulin
  - 8.4.11.4. Market Size and Forecast, By Distribution Channel
- 8.4.12. Rest of Asia-Pacific Human Insulin Market
  - 8.4.12.1. Market Size and Forecast, By Product Type
  - 8.4.12.2. Market Size and Forecast, By Indication
  - 8.4.12.3. Market Size and Forecast, By Type of Insulin
  - 8.4.12.4. Market Size and Forecast, By Distribution Channel

## 8.5. LAMEA

- 8.5.1. Key Market Trends and Opportunities
- 8.5.2. Market Size and Forecast, By Product Type
- 8.5.3. Market Size and Forecast, By Indication
- 8.5.4. Market Size and Forecast, By Type of Insulin
- 8.5.5. Market Size and Forecast, By Distribution Channel
- 8.5.6. Market Size and Forecast, By Country
- 8.5.7. Brazil Human Insulin Market
  - 8.5.7.1. Market Size and Forecast, By Product Type
  - 8.5.7.2. Market Size and Forecast, By Indication
  - 8.5.7.3. Market Size and Forecast, By Type of Insulin
  - 8.5.7.4. Market Size and Forecast, By Distribution Channel
- 8.5.8. Saudi Arabia Human Insulin Market
  - 8.5.8.1. Market Size and Forecast, By Product Type
  - 8.5.8.2. Market Size and Forecast, By Indication
  - 8.5.8.3. Market Size and Forecast, By Type of Insulin
  - 8.5.8.4. Market Size and Forecast, By Distribution Channel
- 8.5.9. South Africa Human Insulin Market
  - 8.5.9.1. Market Size and Forecast, By Product Type
  - 8.5.9.2. Market Size and Forecast, By Indication
  - 8.5.9.3. Market Size and Forecast, By Type of Insulin
  - 8.5.9.4. Market Size and Forecast, By Distribution Channel
- 8.5.10. Rest of LAMEA Human Insulin Market
  - 8.5.10.1. Market Size and Forecast, By Product Type
  - 8.5.10.2. Market Size and Forecast, By Indication
  - 8.5.10.3. Market Size and Forecast, By Type of Insulin
  - 8.5.10.4. Market Size and Forecast, By Distribution Channel

## CHAPTER 9: COMPETITIVE LANDSCAPE

- 9.1. Introduction
- 9.2. Top Winning Strategies
- 9.3. Product Mapping of Top 10 Player
- 9.4. Competitive Dashboard
- 9.5. Competitive Heatmap
- 9.6. Top Player Positioning, 2023

## **CHAPTER 10: COMPANY PROFILES**

- 10.1. Eli Lilly And Company
  - 10.1.1. Company Overview
  - 10.1.2. Key Executives
  - 10.1.3. Company Snapshot
  - 10.1.4. Operating Business Segments
  - 10.1.5. Product Portfolio
  - 10.1.6. Business Performance
  - 10.1.7. Key Strategic Moves and Developments
- 10.2. Sanofi
  - 10.2.1. Company Overview
  - 10.2.2. Key Executives
  - 10.2.3. Company Snapshot
  - 10.2.4. Operating Business Segments
  - 10.2.5. Product Portfolio
  - 10.2.6. Business Performance
  - 10.2.7. Key Strategic Moves and Developments
- 10.3. Novo Nordisk A/S
  - 10.3.1. Company Overview
  - 10.3.2. Key Executives
  - 10.3.3. Company Snapshot
  - 10.3.4. Operating Business Segments
  - 10.3.5. Product Portfolio
  - 10.3.6. Business Performance
  - 10.3.7. Key Strategic Moves and Developments
- 10.4. Pfizer
  - 10.4.1. Company Overview
  - 10.4.2. Key Executives
  - 10.4.3. Company Snapshot
  - 10.4.4. Operating Business Segments

- 10.4.5. Product Portfolio
- 10.4.6. Business Performance
- 10.4.7. Key Strategic Moves and Developments
- 10.5. Biocon
  - 10.5.1. Company Overview
  - 10.5.2. Key Executives
  - 10.5.3. Company Snapshot
  - 10.5.4. Operating Business Segments
  - 10.5.5. Product Portfolio
  - 10.5.6. Business Performance
  - 10.5.7. Key Strategic Moves and Developments
- 10.6. Wockhardt
  - 10.6.1. Company Overview
  - 10.6.2. Key Executives
  - 10.6.3. Company Snapshot
  - 10.6.4. Operating Business Segments
  - 10.6.5. Product Portfolio
  - 10.6.6. Business Performance
  - 10.6.7. Key Strategic Moves and Developments
- 10.7. MannKind Corporation
  - 10.7.1. Company Overview
  - 10.7.2. Key Executives
  - 10.7.3. Company Snapshot
  - 10.7.4. Operating Business Segments
  - 10.7.5. Product Portfolio
  - 10.7.6. Business Performance
  - 10.7.7. Key Strategic Moves and Developments
- 10.8. Tonghua Dongbao Pharmaceutical Co., Ltd.
  - 10.8.1. Company Overview
  - 10.8.2. Key Executives
  - 10.8.3. Company Snapshot
  - 10.8.4. Operating Business Segments
  - 10.8.5. Product Portfolio
  - 10.8.6. Business Performance
  - 10.8.7. Key Strategic Moves and Developments
- 10.9. Medtronic
  - 10.9.1. Company Overview
  - 10.9.2. Key Executives
  - 10.9.3. Company Snapshot

- 10.9.4. Operating Business Segments
- 10.9.5. Product Portfolio
- 10.9.6. Business Performance
- 10.9.7. Key Strategic Moves and Developments
- 10.10. Lupin
  - 10.10.1. Company Overview
  - 10.10.2. Key Executives
  - 10.10.3. Company Snapshot
  - 10.10.4. Operating Business Segments
  - 10.10.5. Product Portfolio
  - 10.10.6. Business Performance
  - 10.10.7. Key Strategic Moves and Developments



## I would like to order

Product name: Pain Management Drugs Market By Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Anti-migraine Agents, Antidepressants, Opioids, Nonnarcotic Analgesics) , By Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, Fibromyalgia, Muscle Sprain/Strain, Bone Fracture, Acute Appendicitis, Others) By Pain Type (Chronic Pain, Acute Pain) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Product link: <https://marketpublishers.com/r/P06E1D1C434FEN.html>

Price: US\$ 2,655.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P06E1D1C434FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970